Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin ( NPM1): Comparison with WT1 gene expression

Molecular analysis of minimal residual disease is only applicable in acute myeloblastic leukemia (AML) patients with genetic markers (20–30%). This study analyzes the feasibility of the real-time quantitative polymerase chain reaction (RQ-PCR) assay to detect mutant nucleophosmin ( NPM1) during foll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinica chimica acta 2008-09, Vol.395 (1), p.120-123
Hauptverfasser:	Barragan, Eva, Pajuelo, Juan C., Ballester, Sandra, Fuster, Oscar, Cervera, Jose, Moscardo, Federico, Senent, Leonor, Such, Esperanza, Sanz, Miguel A., Bolufer, Pascual
Format:	Artikel
Sprache:	eng
Schlagworte:	AML Antineoplastic Combined Chemotherapy Protocols - therapeutic use Female Follow-Up Studies Genes, Wilms Tumor Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - therapy Male Middle Aged MRD Mutation Neoplasm, Residual - diagnosis Neoplasm, Residual - genetics Neoplasm, Residual - therapy NPM1 Nuclear Proteins - genetics Polymerase Chain Reaction - methods Recurrence Remission Induction Reproducibility of Results Sensitivity and Specificity Time Factors WT1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!